Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-133874

Published: 2020

Journal Articles

Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function

Justin C. Boucher, PhD, Gongbo Li, PhD MBBS, Hiroshi Kotani, MD PhD, Maria Cabral, Dylan Morrissey, Sae Bom Lee, Kristen Spitler, Nolan Beatty, Bishwas Shrestha, PhD, Bin Yu, Aslamuzzaman Kazi, Xuefeng Wang, PhD, Said Sebti, PhD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 248.

https://doi.org/10.1182/blood-2019-122954

Published: 2019

Journal Articles

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

Farhad Ravandi, MBBS, Deepa Sampath, PhD, William Plunkett, PhD, Betsy Williams, RN, Michelle Burton, RN, Srdan Verstovsek, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Vernon Alvarez, PhD, Michael D Becker, Alan F. List, MD, Said Sebti, PhD, Hagop M. Kantarjian, MD, Jeffrey Lancet, MD

Blood (2008) 112 (11): 2987.

https://doi.org/10.1182/blood.V112.11.2987.2987

Published: 2008

Journal Articles

A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.

Jeffrey E. Lancet, MD, Elliott F. Winton, MD, Robert K. Stuart, MD, Michelle Burton, RN, Christopher Cubitt, PhD, Michelle Blaskovich, John Wright, MD, PhD, Said Sebti, PhD, Daniel Sullivan, MD, MS

Blood (2008) 112 (11): 1945.

https://doi.org/10.1182/blood.V112.11.1945.1945

Published: 2008

Journal Articles

First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia.

P.K. Epling-Burnette, PhD, Lubomir Sokol, MD, Lynn Moscinski, MD, Magda Elkabani, MD, Fanqi Bai, MD, Michelle Blaskovich, BS, JianXiang Zou, MD, Jeffrey S. Painter, BS, Said Sebti, PhD, Thomas P. Loughran, MD

Blood (2007) 110 (11): 3132.

https://doi.org/10.1182/blood.V110.11.3132.3132

Published: 2007

Journal Articles

Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet.

Fanqi Bai, MD, J.-X. Zou, MD, Sheng Wei, MD, Jeffrey S. Painter, BS, Michelle Blaskovich, Bs, Said Sebti, PhD, Thomas P. Loughran, MD, P.K. Epling-Burnette, PhD

Blood (2007) 110 (11): 1331.

https://doi.org/10.1182/blood.V110.11.1331.1331

Published: 2007

Journal Articles

Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance.

Fengdong Cheng, MD, Hongwei Wang, MD, Alfonso Suarez, Pedro Horna, MD, Said Sebti, PhD, Eduardo M. Sotomayor, MD

Blood (2005) 106 (11): 1485.

https://doi.org/10.1182/blood.V106.11.1485.1485

Published: 2005

NARROW

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.

First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia.

Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet.

Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance.

Email alerts

ASH Publications

American Society of Hematology

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.

First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia.

Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet.

Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only